Genomic and Molecular Markers for Patient Stratification

Genomic and molecular markers are critical for patient stratification in interventional cardiology, allowing for tailored treatment strategies based on individual risk factors. By analyzing specific genetic variants and biomarkers, clinicians can assess patients’ susceptibility to cardiovascular events and customize their management accordingly. This personalized approach enhances the precision of therapeutic interventions and improves outcomes. Biomarkers such as high-sensitivity troponin and NT-proBNP aid in early diagnosis and risk assessment. Ongoing research aims to identify new markers that can refine predictive capabilities, ultimately leading to better-targeted therapies for cardiovascular diseases.

    Related Conference of Genomic and Molecular Markers for Patient Stratification

    November 19-20, 2025

    7th World Heart Congress

    Tokyo, Japan
    November 24-25, 2025

    36th Annual Cardiologists Conference

    Barcelona, Spain
    November 27-28, 2025

    32nd World Heartcare Summit

    Paris, France
    January 12-13, 2026

    12th International Heart Conference

    Dubai, UAE
    March 18-19, 2026

    15th World Heart Congress

    Paris, France
    March 23-24, 2026

    41st World Cardiology Conference

    London, UK
    April 08-29, 2026

    9th Annual Heart Rhythm Conference

    Vienna, Austria
    April 13-14, 2026

    9th World Heart and Brain Conference

    Tokyo, Japan
    May 14-15, 2026

    5th International Conference on Cardiology

    Rome, Italy
    May 21-22, 2026

    15th World Congress on Cardiology

    London, UK
    July 29-30, 2026

    30th World Cardiology Conference

    Paris, France

    Genomic and Molecular Markers for Patient Stratification Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in